TITLE

1

2 Synonymous sites in SARS-CoV-2 genes display trends affecting translational efficiency

3 **AUTHORS**

- 4 Qingsheng Huang^{1*}, Huan Gao^{1*}, Lingling Zheng¹, Xiujuan Chen¹, Shuai Huang¹,
- 5 Huiying Liang¹†

6 **AFFILIATIONS**

- ¹Institute of Pediatrics, Guangzhou Women and Children's Medical Centre, Guangzhou
- 8 Medical University, Guangzhou, 510623, China.
- 9 *These authors contributed equally to this work.
- †Correspondence to: Huiying Liang (lianghuiying(AT)hotmail.com)

11 **ABSTRACT**

- 12 A novel coronavirus, SARS-CoV-2, has caused a pandemic of COVID-19. The
- evolutionary trend of the virus genome may have implications for infection control policy
- but remains obscure. We introduce an estimation of fold change of translational
- efficiency based on synonymous variant sites to characterize the adaptation of the virus to
- hosts. The increased translational efficiency of the M and N genes suggests that the
- population of SARS-CoV-2 benefits from mutations toward favored codons, while the
- ORF1ab gene has slightly decreased the translational efficiency. In the coding region of
- 19 the ORF1ab gene upstream of the -1 frameshift site, the decreasing of the translational
- 20 efficiency has been weakening parallel to the growth of the epidemic, indicating
- inhibition of synthesis of RNA-dependent RNA polymerase and promotion of replication
- of the genome. Such an evolutionary trend suggests that multiple infections increased
- virulence in the absence of social distancing.

INTRODUCTION

25

26 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a previously unknown 27 coronavirus, has caused the pandemic of coronavirus disease 2019 (COVID-19) since 28 December 2019(1-4). Coronaviruses are positive-sense single-stranded RNA viruses with envelopes. The reference genome of SARS-CoV-2 (NCBI accession NC 045512) has 29 30 29,903 nucleotides (nt) containing ORF1ab (also known as NSP, non-structural protein), S (surface or spike), E (envelope), M (membrane or matrix), N (nucleocapsid), and other 31 32 seven putative open reading frames (ORFs)(2, 3). Comparisons between genomes of 33 SARS-CoV-2 and related viruses have revealed many important insights about the origin of SARS-CoV-2(5-8), but there are few studies on how the genome of SARS-CoV-2 will 34 35 evolve in the initial stage of the pandemic, which may have implications for infection control policy (9). 36 Codon usage of viral genes is subject to selection pressures imposed by the gene 37 translation machinery of hosts (10, 11). Spontaneous mutation, fine-tuning of translation 38 39 kinetics, and evasion of immune recognition together shape the evolutionary trend of 40 codon usage (12). Traditional methods based on relative synonymous codon usage 41 (RSCU)(13, 14) count the frequencies of codons of virus genes and evaluate the 42 adaptation to the hosts. However, the sparsity of single nucleotide variants (SNVs) in 43 genomes of SARS-CoV-2 precludes the traditional methods, which were designed for comparison between distant species, from extracting the subtle trend. Here, we introduce 44 45 a method based on fold change of translational efficiency (FCTE), which accumulates the effects of synonymous SNV distributed sparsely in the genome of SARS-CoV-2 and 46 characterize the adaptation to hosts in the epidemic in China. 47

RESULTS

48

49 Density of SNV in the coding regions of SARS-CoV-2

- In 12 ORFs of SARS-CoV-2, there are on average only 0.021 nonsynonymous sites and
- 51 0.012 synonymous sites per 1000 nt per genome (Fig. 1A). The numbers of synonymous

and nonsynonymous sites in a coding region are both correlated with the length of the 52 coding region (Fig. 1B). Compare to the average mutation density, ORF1ab:A, which is 53 54 the coding region of the ORF1ab gene upstream of the -1 frameshift site, contains slightly more synonymous sites, while ORF1ab:B, which is downstrem of the -1 frameshift site, 55 contains less synonymous sites. 56 57 FCTE of synonymous mutation FCTE measures the effect of mutation on the translation of the residing gene. We 58 estimated FCTE by the fold change of codon usage frequencies of the codon pair before 59 and after a synonymous mutation (Table S1). The codon usage frequency was calibrated 60 by the codon frequency averaged over a repertoire of genes weighted by their expression 61 62 levels in the type II alveolar (AT2) cells of lung tissue, which is probably the target cells of SARS-CoV-2(15). Two topologies of phylogenetic trees of the genomes of SARS-63 CoV-2 were examined. The first topology is star-like, in which the central ancestor is the 64 consensus sequence (Fig. 2A). The second topology is a maximum likelihood tree rooted 65 66 at the earliest collected genome, in which a mutation is defined as a pair of codon states 67 in the parent and child nodes (Fig. S1, Fig. 2B). FCTE of mutations were grouped by the residing coding regions and the effects of 68 mutations on the translation were evaluated. The Wilcoxon tests yield almost the same p 69 values, pseudomedians, and nonparametric 95% confidence intervals for a coding region 70 71 considered in different topologies, suggesting that FCTE is insensitive to the topologies 72 of the phylogenetic trees (Fig. 2, C and D). Despite of the ORF6 and ORF7b genes which have no synonymous sites, evolutionary stability of translational efficiency of the S, 73 ORF3a, E, ORF7a, ORF8, and ORF10 genes withstands the Wilcoxon tests. For the M 74 and N genes, the pseudomedians of log₂ FCTE are 0.45 and 0.68, respectively, suggesting 75 that during the evolution in the epidemic, the population of SARS-CoV-2 benefits from 76

mutations toward codons favored by the hosts, which possibly accelerate the translation

of these genes. In the ORF1ab gene, synonymous sites have evolved toward unfavored

codons, especially in the ORF1ab:A fragment.

77

78

Evolutionary trends of ORF1ab

80

91

103

- To demonstrate the relationship between log₂ FCTE of mutations and the collection times
- of the genomes in China, we fitted linear models to mutations in the ORF1ab:A and
- ORF1ab:B fragments and the full-length ORF1ab gene (Fig. 3). The evolutionary trend of
- the ORF1ab:A fragment is parallel to the growth of the epidemic (Fig. 3A). The
- ORF1ab:B fragment shows an evolutionary trend opposite to the ORF1ab:A fragment. A
- summation of ORF1ab:A and ORF1ab:B, however, obscures the evolutionary trend of
- 87 the full-length ORF1ab. Examined in context of the maximum likelihood tree rooted at
- the earliest collected genome, the opposite evolutionary trends of ORF1ab:A and
- ORF1ab:B are even significant, i.e., the p values of the fitted linear models are both
- below 0.05 and the correlation coefficients get larger (Fig. 3B).

Estimation of FCTE for average lung tissue

- We estimated FCTE by codon usage frequencies calibrated for average lung tissue (Table
- 93 S1). The values of codon usage frequencies are similar to those for the AT2 cells. The
- 94 FCTE of genes (Fig. S2, A, B, E, and F) and the evolutionary trend of the two fragments
- 95 of ORF1ab (Fig. S3, A and B) are similar to previous results calibrated for the AT2 cells,
- 96 except that the statistical tests against the evolutionary tendency of the N gene and the
- evolutionary trend of ORF1ab:A become non-significant (Fig. S2, E and F, and Fig. S3B).
- We also estimated FCTE by codon usage frequencies calibrated for human genes without
- 99 weighting (16). Although the values of codon usage frequencies are similar to those for
- the AT2 cells and for average lung tissue, the statistical tests against the evolutionary
- tendency of the M and N gene and the evolutionary trend of ORF1ab:A are non-
- significant (Fig. S2, G and H, and Fig. S3D).

DISCUSSION

- Usage of synonymous codons is non-random and non-uniform, the so-called codon bias,
- the extend of which varies among genes and species (17). Codon bias distinguishes
- expression levels of genes (13, 18). Codon usage of the viral genes might be subject to
- selection pressures imposed by the gene translation machinery of the host, because the

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

virus relies on ribosomes and tRNAs of the host cells(12). For human, genes encoding tRNA of various codons are scattered throughout all but the Y chromosome. Relative tRNA abundance, as a result of the number of tRNA genes and the expression levels of these tRNA genes, have been proved correlated significantly to the codon usage of highly expressed genes in a tissue-specific manner (19). Since we do not have the tRNA abundance data for lung tissues, we estimate the change of translational efficiency by the change of codon usage in expressed genes in the AT2 cells and in average lung tissue. Although such an estimation may be even more suitable for evaluation of adaptation of virus genome, because the codon usage frequency also reflects the stability of interactions between mRNA and anticodon in addition to tRNA abundance(12), an direct measurement of tRNA abundance may help to further address various effects of translation kinetics. FCTE in the M and N genes confirm the adaptation of the genome of SARS-CoV-2 to the target tissue (12, 20). Translation products of the M and N genes, both the most abundant structural proteins, interact with the genomic RNA intimately in the viral replication and virion packaging (21, 22). By contrast, synonymous sites in the S gene suggest no tendency of translational efficiency, which can be explained by the fact that the S protein plays no roles in the replication and only a passive role in the packaging. Selection pressure detected in the M and N genes may nullify previous studies on the virus evolution based on the nonsynonymous-to-synonymous site ratio (Ka/Ks test), though speculations on the evolution of the S gene still holds. The ORF1ab gene contains a ribosomal -1 frameshift site (Fig. 1A)(23). When the frameshifting is urged, the product is the ORF1ab protein, which can be further processed to produce RNA-dependent RNA polymerase (RdRp). The newly generated RdRp protein starts synthesizing the complementary strand from the 3' end of the genomic RNA and disrupts long distance pairing of RNA secondary structure, preventing the frameshifting in later translation(24). So the ribosome will encounter a stop codon soon and the product is the ORF1a protein contains no RdRp. By such a mechanism the virus encourages RdRp to replicate the genomic RNA which is free of hindering ribosomes. Although synonymous site may changing the RNA secondary structure(23), we observed

only one synonymous site appeared in the stem-loop regions overlapped with the ORF1ab gene in one genome (20). A tendency of mutation to rare codons shown by the negative value of log₂ FCTE of the ORF1ab:A fragment (Fig. 2, C and D) imply that SARS-CoV-2 has slowed down the translation and enhanced the -1 frameshifting, producing redundant RdRp and distracting virus replication. According to the SIR (susceptible-infected-recovered) epidemiological model, such a tendency may be evolutionarily beneficial to the virus when the distraction of virus replication assists immune evasion or reduces the mortality rate of the hosts, but is essentially evolutionarily unfavored if there were multiple infections and competition (25). In such cases, the genome will be cheated by peers without rare codons in the ORF1ab:A fragment, which produce few RdRp proteins and replicate their genomic RNA with redundant RdRp produced by the cheatee. Parallel to the growth of the epidemic(4) which might increase the possibility of multiple infections, the tendency of mutation toward rare codons in the ORF1ab: A region was weakening in the SARS-CoV-2 epidemic in China (Fig. 3B). Hinged by the fine-tuning of FCTE of the ORF1ab: A region, multiple infections break the balance between RdRp production and genome replication, and may drive the evolution of efficient replication. Because high abundance of virus in an infected host increases the virulence and delays the host curing the infection (25), prevention against multiple infection seems to be a precondition for taming the virus, may provide a new theoretical basis for social distancing in addition to reducing the infected population (26).

MATERIALS AND METHODS

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

Codon usage frequency in the AT2 cells and in lung

The codon usage frequency was calibrated by the averaged frequency of codons in a repertoire of genes weighted by the expression levels. SARS-CoV-2 mainly infects lung tissue, and probably targets the type II alveolar (AT2) cells(15). A dataset of single-cell transcriptome of human lung tissue (GEO: GSE122960)(27) was re-analysis with R package Seurat version 3.1.4(28) following a previous study(15). Briefly, high-quality cells from eight donor lung biopsies were extracted, which have 200 to 6,000 detected genes and their mitochondrial gene content was <10%, and genes detected in less than

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186 187

188

189

190

191

192

193

194

three cells were discarded. The gene-cell matrices from eight donor lung biopsies were integrated by SCT normalization method with 2000 anchor genes. By a shared 20-nearest neighbor graph constructed with the first 30 principle components, the cells were clustered at a resolution of 0.15. The AT2 cluster was identified by comparing the marker genes found by the function FindAllMarkers() to marker genes reported by Reyfman et al.(27) For each AT2 cell, the frequency of codons in high-quality cells were counted according to coding DNA sequences of GRCh38.84 provided by ENSEMBL(29). Codon usage frequency in an AT2 cell was calculated by the frequency of codons averaged among genes weighted by the expression levels. Codon usage frequency in all AT2 cells was averaged and used in subsequent analysis. In addition, we also calculated codon usage frequency for the average lung tissue. A dataset of the expression level of transcripts measured as TPM in lung tissue was downloaded from GTEx portal (version 8)(30). The corresponding transcript sequences were obtained from GENCODE version 26(31). Codon usage frequency in a biopsy was calculated by the averaged frequency of codons weighted by the expression levels. Codon usage frequency in lung tissue was averaged over 578 biopsies, of which the autolysis score was 0 or 1, the donor was 20 to 59 years old, and the death Hardy Scale was 1 or 2. Multiple sequence alignment and phylogenetic analysis We downloaded 623 sequences from GISAID's EpiCoVTM (http://www.gisaid.org, last visit on 13 March 2020, External Data S1), and obtained the sequence and annotations of the reference genome of SARS-CoV-2 from NCBI (accession: NC 045512) (1). A multiple sequence alignment (MSA) of 516 genome sequences (sequences of more than 29000 nt) was built using MUSCLE version 3.8.31(32) with default setting. The MSA was trimmed, removing nucleotides preceding the first ORF (ORF1ab) and following the last ORF (ORF10). For quality control, we discarded genomes of which the collection date was ambiguous or the sequence contained any gaps or more than one unresolved nucleotide (symbol "N"), which also included genomes collected from pangolins and bats. The refined MSA consists of 317 sequences.

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

A maximum likelihood phylogenetic tree of the 317 sequences was built using RAxML-NG version 0.9.0(33) with GTR+G substitution model and bootstrapping with MREbased convergence criterion up to 1000 replicates. The tree was essentially unrooted, and we rooted the tree at the earliest collected sample (EPI ISL 402123) (Fig. S1). Synonymous triplet sites Codon triplets on 12 ORFs and two fragments of ORF1ab, the fragments of ORF1ab:A and ORF1ab:B, totally 14 coding regions were examined (Fig. 1). In the 12 ORFs, 366 SNV triplet sites among 317 genomes distribute in the coding regions uniformly (Fig. 1A). The numbers of nonsynonymous and synonymous sites in a coding region are both correlated with the length of the coding region (Fig. 1B). In columns of the MSA of a coding region, the frequency of codons was counted. For a synonymous triplet site, the states before and after a mutation were defined by two topologies of the phylogenetic tree of the virus genomes. The first topology was star-like, in which all 317 genomes as nodes were individually connected to the root, which was the consensus sequence of the 317 genomes. A pair of states of a synonymous site before and after the mutation was the consensus codon versus the minority codon, which was the codon in a few virus genomes different from the consensus. Identical minority codons in different genomes were counted separately as pairs of states of the mutation. Minority codons that contained any partial ambiguity symbols were neglected. The star-like topology might blur the evolutionary trend, because it counted descendant of a synonymous mutation several times. The second topology of the phylogenetic tree of the virus genomes was a maximum likelihood tree rooted at the earliest collected genome (Fig. S1). For a synonymous triplet site, the maximum likelihood ancestor states in internal nodes of the tree were reconstructed using R package phangorn version 2.5.5 (34). Pairs of states of a synonymous site before and after the mutation were defined for edges whose two ends had different codons, i.e., the sum of absolute difference of reconstructed probability of states of codons was greater than 1. The ancestral and mutational states of the edge were

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

the codon of the parent and the child nodes, respectively. The number of descendants of the child node indicates the prosperity of the mutation. Fold change of translational efficiency (FCTE) FCTE characterizes the tendency of codon usage bias in coding regions. In this study, we estimated FCTE by the fold change of codon usage frequency before and after a synonymous mutation (Fig. 2, A and B). Synonymous sites of a coding region were grouped by the residing coding regions, and we performed a one-sample exact Wilcoxon test to see if translational efficiency of the coding region was evolutionary stable (Fig. 2, C and D). We plotted log₂ FCTE of mutations in the ORF1ab gene against collection times of the virus genomes. For displaying the parallel development of FCTE of mutations with epidemic (Fig. 3), we extracted from World Health Organization's report on COVID-19 the epidemic curve of clinical diagnosed cases, which include laboratory confirmed cases, in Wuhan (4). In addition to the FCTE estimated by codon usage frequency of AT2 cells, we also calculated the FCTE by codon usage frequency for average lung tissue and for all human genes without weighting (Fig. S2 and S3). Statistical Analysis We implemented scripts for finding synonymous triplet sites and calculating FCTE with R version 3.6.2. To evaluate the evolutionary stability of the translational efficiency of a coding region, synonymous sites of the coding region were grouped by the residing coding regions, and a one-sample exact Wilcoxon test was performed to see if the distribution of the logarithm to base 2 (log₂) of FCTE of a region was symmetric about zero. Along with the Wilcoxon tests, pseudomedians and the nonparametric 95% confidence intervals were reported except for the M gene, of which the small sample size precluded the estimation of a 95% confidence interval (Fig. 2, C and D). To demonstrate the evolutionary trend of translational efficiency of the ORF1ab gene, the mutations were

- 250 fitted by linear models. We reported the correlation coefficients (R^2) of the linear models
- and performed *F*-tests to show the overall significance (Fig. 3).

REFERENCES AND NOTES

- 253 1. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi,
- R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, I. China
- Novel Coronavirus, T. Research, A novel coronavirus from patients with pneumonia in
- 256 China, 2019. N. Engl. J. Med. 382, 727-733 (2020).
- 257 2. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-
- H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng,
- L. Xu, E. C. Holmes, Y.-Z. Zhang, A new coronavirus associated with human respiratory
- 260 disease in China. *Nature* **579**, 265-269 (2020).
- 261 3. J. F. Chan, S. Yuan, K. H. Kok, K. K. To, H. Chu, J. Yang, F. Xing, J. Liu, C. C.
- 262 Yip, R. W. Poon, H. W. Tsoi, S. K. Lo, K. H. Chan, V. K. Poon, W. M. Chan, J. D. Ip, J.
- P. Cai, V. C. Cheng, H. Chen, C. K. Hui, K. Y. Yuen, A familial cluster of pneumonia
- associated with the 2019 novel coronavirus indicating person-to-person transmission: a
- study of a family cluster. *Lancet* **395**, 514-523 (2020).
- 266 4. WHO-China Joint Mission, Report of the WHO-China Joint Mission on
- 267 *Coronavirus Disease 2019 (COVID-19)*, (2020).
- D. Benvenuto, M. Giovanetti, A. Ciccozzi, S. Spoto, S. Angeletti, M. Ciccozzi,
- The 2019-new coronavirus epidemic: Evidence for virus evolution. J. Med. Virol. 92,
- 270 455-459 (2020).

- 271 6. C. Ceraolo, F. M. Giorgi, Genomic variance of the 2019 nCoV coronavirus. J.
- 272 Med. Virol., (2020).
- 273 7. X. Tang, C. Wu, X. Li, Y. Song, X. Yao, X. Wu, Y. Duan, H. Zhang, Y. Wang, Z.
- Qian, J. Cui, J. Lu, On the origin and continuing evolution of SARS-CoV-2. *Natl. Sci.*
- 275 Rev., (2020).
- 276 8. P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu,
- B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y.
- 278 Chen, X. R. Shhotmailen, X. Wang, X. S. Zheng, K. Zhao, Q. J. Chen, F. Deng, L. L. Liu,
- B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A pneumonia outbreak associated
- with a new coronavirus of probable bat origin. *Nature* **579**, 270-273 (2020).
- 281 9. P. Forster, L. Forster, C. Renfrew, M. Forster, Phylogenetic network analysis of
- SARS-CoV-2 genomes. Proc. Natl. Acad. Sci. U.S.A., (2020).
- 283 10. N. Stoletzki, A. Eyre-Walker, Synonymous codon usage in Escherichia coli:
- selection for translational accuracy. *Mol. Biol. Evol.* **24**, 374-381 (2007).
- 285 11. T. Ikemura, Codon usage and tRNA content in unicellular and multicellular
- 286 organisms. *Mol. Biol. Evol.* **2**, 13-34 (1985).
- 287 12. E. H. Wong, D. K. Smith, R. Rabadan, M. Peiris, L. L. Poon, Codon usage bias
- and the evolution of influenza A viruses. Codon Usage Biases of Influenza Virus. BMC
- 289 Evol. Biol. 10, 253 (2010).

- 290 13. P. M. Sharp, T. M. Tuohy, K. R. Mosurski, Codon usage in yeast: cluster analysis
- clearly differentiates highly and lowly expressed genes. *Nucleic Acids Res.* **14**, 5125-
- 292 5143 (1986).
- 293 14. P. M. Sharp, W. H. Li, The codon Adaptation Index--a measure of directional
- synonymous codon usage bias, and its potential applications. *Nucleic Acids Res.* **15**,
- 295 1281-1295 (1987).
- 296 15. Y. Zhao, Z. Zhao, Y. Wang, Y. Zhou, Y. Ma, W. Zuo, Single-cell RNA
- expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. *BioRxiv*,
- 298 (2020).
- 299 16. Y. Nakamura, T. Gojobori, T. Ikemura, Codon usage tabulated from international
- DNA sequence databases: status for the year 2000. *Nucleic Acids Res.* **28**, 292 (2000).
- 301 17. J. M. Comeron, M. Aguade, An evaluation of measures of synonymous codon
- 302 usage bias. J. Mol. Evol. 47, 268-274 (1998).
- 303 18. I. Henry, P. M. Sharp, Predicting gene expression level from codon usage bias.
- 304 *Mol. Biol. Evol.* **24**, 10-12 (2007).
- 305 19. K. A. Dittmar, J. M. Goodenbour, T. Pan, Tissue-specific differences in human
- transfer RNA expression. *PLoS Genet.* **2**, e221 (2006).
- 20. C. Polte, D. Wedemeyer, K. E. Oliver, J. Wagner, M. J. C. Bijvelds, J. Mahoney,
- 308 H. R. de Jonge, E. J. Sorscher, Z. Ignatova, Assessing cell-specific effects of genetic
- variations using tRNA microarrays. *BMC Genomics* **20**, 549 (2019).
- 21. C. K. Chang, M. H. Hou, C. F. Chang, C. D. Hsiao, T. H. Huang, The SARS
- coronavirus nucleocapsid protein--forms and functions. *Antiviral Res.* **103**, 39-50 (2014).
- 312 22. H. Jayaram, H. Fan, B. R. Bowman, A. Ooi, J. Jayaram, E. W. Collisson, J.
- Lescar, B. V. Prasad, X-ray structures of the N- and C-terminal domains of a coronavirus
- nucleocapsid protein: implications for nucleocapsid formation. J. Virol. **80**, 6612-6620
- 315 (2006).
- 316 23. O. Namy, S. J. Moran, D. I. Stuart, R. J. Gilbert, I. Brierley, A mechanical
- 317 explanation of RNA pseudoknot function in programmed ribosomal frameshifting.
- 318 *Nature* **441**, 244-247 (2006).
- 319 24. J. F. Atkins, G. Loughran, P. R. Bhatt, A. E. Firth, P. V. Baranov, Ribosomal
- frameshifting and transcriptional slippage: From genetic steganography and cryptography
- 321 to adventitious use. *Nucleic Acids Res.* **44**, 7007-7078 (2016).
- 25. C. E. Cressler, L. D. Mc, C. Rozins, V. D. H. J, T. Day, The adaptive evolution of
- virulence: a review of theoretical predictions and empirical tests. *Parasitology* **143**, 915-
- 324 930 (2016).
- 325 26. S. Cobey, Modeling infectious disease dynamics. *Science*, (2020).
- 27. P. A. Reyfman, J. M. Walter, N. Joshi, K. R. Anekalla, A. C. McQuattie-Pimentel,
- 327 S. Chiu, R. Fernandez, M. Akbarpour, C. I. Chen, Z. Ren, R. Verma, H. Abdala-Valencia,
- 328 K. Nam, M. Chi, S. Han, F. J. Gonzalez-Gonzalez, S. Soberanes, S. Watanabe, K. J. N.
- Williams, A. S. Flozak, T. T. Nicholson, V. K. Morgan, D. R. Winter, M. Hinchcliff, C.
- L. Hrusch, R. D. Guzy, C. A. Bonham, A. I. Sperling, R. Bag, R. B. Hamanaka, G. M.
- Mutlu, A. V. Yeldandi, S. A. Marshall, A. Shilatifard, L. A. N. Amaral, H. Perlman, J. I.
- 332 Sznajder, A. C. Argento, C. T. Gillespie, J. Dematte, M. Jain, B. D. Singer, K. M. Ridge,
- A. P. Lam, A. Bharat, S. M. Bhorade, C. J. Gottardi, G. R. S. Budinger, A. V. Misharin,
- 334 Single-cell transcriptomic analysis of human lung provides insights into the pathobiology
- 335 of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 199, 1517-1536 (2019).

- 336 28. T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck, 3rd,
- Y. Hao, M. Stoeckius, P. Smibert, R. Satija, Comprehensive integration of single-cell
- 338 data. Cell 177, 1888-1902 e1821 (2019).
- 339 29. A. Yates, W. Akanni, M. R. Amode, D. Barrell, K. Billis, D. Carvalho-Silva, C.
- Cummins, P. Clapham, S. Fitzgerald, L. Gil, C. G. Giron, L. Gordon, T. Hourlier, S. E.
- Hunt, S. H. Janacek, N. Johnson, T. Juettemann, S. Keenan, I. Lavidas, F. J. Martin, T.
- Maurel, W. McLaren, D. N. Murphy, R. Nag, M. Nuhn, A. Parker, M. Patricio, M.
- Pignatelli, M. Rahtz, H. S. Riat, D. Sheppard, K. Taylor, A. Thormann, A. Vullo, S. P.
- Wilder, A. Zadissa, E. Birney, J. Harrow, M. Muffato, E. Perry, M. Ruffier, G. Spudich,
- 345 S. J. Trevanion, F. Cunningham, B. L. Aken, D. R. Zerbino, P. Flicek, Ensembl 2016.
- 346 Nucleic Acids Res. 44, D710-716 (2016).
- 347 30. The Genotype-Tissue Expression (GTEx) Project was supported by the Common
- Fund of the Office of the Director of the National Institutes of Health, and by NCI,
- NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in
- this manuscript were obtained from the GTEx Portal on Aug. 27, 2019.
- 31. A. Frankish, M. Diekhans, A. M. Ferreira, R. Johnson, I. Jungreis, J. Loveland, J.
- 352 M. Mudge, C. Sisu, J. Wright, J. Armstrong, I. Barnes, A. Berry, A. Bignell, S. Carbonell
- 353 Sala, J. Chrast, F. Cunningham, T. Di Domenico, S. Donaldson, I. T. Fiddes, C. Garcia
- Giron, J. M. Gonzalez, T. Grego, M. Hardy, T. Hourlier, T. Hunt, O. G. Izuogu, J.
- Lagarde, F. J. Martin, L. Martinez, S. Mohanan, P. Muir, F. C. P. Navarro, A. Parker, B.
- Pei, F. Pozo, M. Ruffier, B. M. Schmitt, E. Stapleton, M. M. Suner, I. Sycheva, B.
- Uszczynska-Ratajczak, J. Xu, A. Yates, D. Zerbino, Y. Zhang, B. Aken, J. S. Choudhary,
- 358 M. Gerstein, R. Guigo, T. J. P. Hubbard, M. Kellis, B. Paten, A. Reymond, M. L. Tress, P.
- Flicek, GENCODE reference annotation for the human and mouse genomes. *Nucleic*
- 360 Acids Res. 47, D766-D773 (2019).
- 361 32. R. C. Edgar, MUSCLE: multiple sequence alignment with high accuracy and high
- 362 throughput. *Nucleic Acids Res.* **32**, 1792-1797 (2004).
- 363 33. A. M. Kozlov, D. Darriba, T. Flouri, B. Morel, A. Stamatakis, RAxML-NG: a fast,
- scalable and user-friendly tool for maximum likelihood phylogenetic inference.
- 365 Bioinformatics (Oxford, England) **35**, 4453-4455 (2019).
- 366 34. K. P. Schliep, phangorn: phylogenetic analysis in R. Bioinformatics (Oxford,
- 367 England) **27**, 592-593 (2011).

369


ACKNOWLEDGMENTS

- General: We acknowledge the researchers originating and submitting the sequences from
- 371 GISAID's EpiCoVTM on which this study is based (External Data S1).
- Funding: This work was supported by National Key R&D Plan (No.
- 373 2018YFC1315400.2, to HL).

Author contributions: QH and HL conceived the study. QH and HG contributed implementation of the methods and data analysis. LZ, XC, and SH contributed the data collection. QH and HG prepared the manuscript. All authors read and approved the manuscript.

Competing interests: Authors declare no competing interests.

FIGURES AND TABLES






Fig. 1. Variant sites in coding regions of the genome of SARS-CoV-2. (A)
Organization of coding regions in the genome and locations of variant triplet sites. (B)
Numbers of nonsynonymous and synonymous sites in coding regions.




Fig. 2. Synonymous sites and fold change of translational efficiency (FCTE). (A)

Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the star-like tree in the ORF1ab:A and ORF1ab:B fragments and the M and N genes. (**B**) Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the maximum likelihood tree rooted at the earliest collected genome in the ORF1ab:A and ORF1ab:B fragments and the M and N genes. The width of a segment is roughly in proportion to the number of the same mutations in different genomes in the star-like tree or to the prosperity of a mutation in the maximum likelihood tree. Some labels of codons are neglected for clarity. (**C**) FCTE for the star-like tree. (**D**) FCTE for the maximum likelihood tree. Gray points indicate log₂ FCTE values of mutations, whose pseudomedians are indicated by vertical bars. For coding regions where the Wilcoxon tests reject the null hypothesis that the log₂ FCTE is zero, the vertical bars are colored red and black boxes are added indicating the nonparametric 95% confidence intervals (except the M gene).





Fig. 3. Evolutionary trends of log₂ fold change of translational efficiency (FCTE) of synonymous sites in the ORF1ab gene. (A) log₂ FCTE for the star-like tree plotted against collection time of the genomes. (B) log₂ FCTE for the maximum likelihood tree plotted against collection time of the genomes. Mutation in genomes collected in China are highlighted with green up-pointing triangles for mutations in ORF1ab:A and blue down-pointing triangles for mutations in ORF1ab:B, with fitted lines. Black lines are fitted to both the green and blue triangle. The numbers of mutations (n), p values of the linear models, and correlation coefficients (R2) are shown. Samples collected elsewhere are shown as gray circles. Vertical dotted lines indicate the dates of Wuhan lockdown (23 Jan. 2020) and Italy lockdown (9 March 2020). The backgrounded histogram shows the numbers of clinical diagnosed cases in Wuhan reported by WHO (4).

SUPPLEMENTARY MATERIALS



Fig. S1. The maximum likelihood tree of 317 virus genomes rooted at the earliest collected virus (EPI_ISL_402123). Accession ID from GISAID's EpiCoV™ database is colored black if the virus was collected before 31 Dec. 2019, red if between 31 Dec. 2019 and 23 Jan. 2020 (the date of Wuhan lockdown), green if between 23 Jan. 2020 and 9 March 2020 (Italy lockdown), and blue if after 9 March 2020.



425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

Fig. S2. Synonymous sites and fold change of translational efficiency (FCTE) with gene expression levels calibrated for lung tissue and without tissue specificity. (A) Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the starlike tree in the ORF1ab:A and ORF1ab:B fragments and the M and N genes with gene expression levels calibrated for lung tissue. (B) Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the maximum likelihood tree rooted at the earliest collected genome in the ORF1ab:A and ORF1ab:B fragments and the M and N genes with gene expression levels calibrated for lung tissue. (C) Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the star-like tree in the ORF1ab: A and ORF1ab: B fragments and the M and N genes without tissue specificity. (D) Pairs of ancestral (Anc.) versus mutational (Mut.) states of synonymous sites for the maximum likelihood tree rooted at the earliest collected genome in the ORF1ab:A and ORF1ab:B fragments and the M and N genes without tissue specificity. The width of a segment is roughly in proportion to the number of the same mutations in different genomes in the star-like tree or to the prosperity of a mutation in the maximum likelihood tree. Some labels of codons are neglected for clarity. (E) FCTE for the star-like tree with gene expression levels calibrated for lung tissue. (F) FCTE for the maximum likelihood tree with gene expression levels calibrated for lung tissue. (G) FCTE for the star-like tree without tissue specificity. (H) FCTE for the maximum likelihood tree without tissue specificity. Gray points indicate log₂ FCTE values of mutations, whose pseudomedians are indicated by vertical bars. For coding regions where the Wilcoxon tests reject the null hypothesis that the log₂ FCTE is zero, the vertical bars are colored red and black boxes are added indicating the nonparametric 95% confidence intervals (except the M gene).




Fig. S3. Evolutionary trends of log₂ fold change of translational efficiency (FCTE) of synonymous sites in the ORF1ab gene with gene expression levels calibrated for lung tissue and without tissue specificity. (A) log₂ FCTE for the star-like tree plotted against collection time of the genomes with gene expression levels calibrated for lung tissue. (B) log₂ FCTE for the maximum likelihood tree plotted against collection time of the genomes with gene expression levels calibrated for lung tissue. (C) log₂ FCTE for the star-like tree plotted against collection time of the genomes without tissue specificity. (D) log₂ FCTE for the maximum likelihood tree plotted against collection time of the genomes without tissue specificity. Mutation in genomes collected in China are highlighted with green up-pointing triangles for mutations in ORF1ab:A and blue down-

pointing triangles for mutations in ORF1ab:B, with fitted lines. Black lines are fitted to both the green and blue triangle. The numbers of mutations (n), p values of the linear models, and correlation coefficients (R^2) are shown. Samples collected elsewhere are shown as gray circles. Vertical dotted lines indicate the dates of Wuhan lockdown (23 Jan. 2020) and Italy lockdown (9 March 2020).

Table S1. Codon usage frequency table used for estimation of fold change of translational efficiency (FCTE).

TAA	Codon	Amino	AT2 cell		Lung		Human**	
TAA								
TAG Stop 0.7 1.86 0.6 1.99 0.8 23.5 TGA 1.6 43.7 1.3 43.0 1.6 47.1 GCT 21.2 29.1 19.9 26.9 18.4 26.6 GCC A 16.3 22.4 14.5 19.6 15.8 22.8 GCG 6.3 8.7 8.1 10.9 7.4 10.7 TGT C 9.3 44.8 8.6 41.4 10.6 45.7 TGC 11.4 55.2 12.2 58.6 12.6 54.3 GAT D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG B 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4 TTC <th></th> <th></th> <th>(‰)</th> <th>(%)</th> <th>(‰)</th> <th>(%)</th> <th>(‰)</th> <th>(%)</th>			(‰)	(%)	(‰)	(%)	(‰)	(%)
TGA 1.6 43.7 1.3 43.0 1.6 47.1 GCT 21.2 29.1 19.9 26.9 18.4 26.6 GCC A 16.3 22.4 14.5 19.6 15.8 22.8 GCG 6.3 8.7 8.1 10.9 7.4 10.7 TGT C 9.3 44.8 8.6 41.4 10.6 45.7 TGC C 11.4 55.2 12.2 58.6 12.6 54.3 GAT D 23.9 50.2 21.8 43.4 21.8 46.5 GAC D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG B 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4	TAA	Stop	1.4	37.7	1.1	37.1	1.0	29.4
GCT GCC GCC GCA GCA GCA A 163 GCA	TAG			18.6		19.9		23.5
GCC GCA GCA A 29.0 39.8 31.6 42.6 27.7 40.0 GCA GCG 6.3 22.4 14.5 19.6 15.8 22.8 GCG 6.3 8.7 8.1 10.9 7.4 10.7 TGC C 9.3 44.8 8.6 41.4 10.6 45.7 TGC 11.4 55.2 12.2 58.6 12.6 54.3 GAT D 23.9 50.2 21.8 43.4 21.8 46.5 GAC D 23.8 49.8 28.4 56.6 25.1 53.5 GAG B 31.2 44.6 26.6 37.6 29.0 42.3 GAG B 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4	TGA		1.6	43.7	1.3	43.0	1.6	47.1
GCA GCG GCG GCG GCG GCG GCG GCG GCG GCG	GCT		21.2	29.1	19.9	26.9	18.4	26.6
GCA GCG GCG GCG GCG GCG GCG GCG GCG GCG	GCC	٨	29.0	39.8	31.6	42.6	27.7	40.0
TGT C 9.3 44.8 8.6 41.4 10.6 45.7 TGC 11.4 55.2 12.2 58.6 12.6 54.3 GAT D 23.9 50.2 21.8 43.4 21.8 46.5 GAC D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4 TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC 24.4 35.2 26.9 37.2 22.2 23.36. GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT	GCA	Α	16.3	22.4	14.5	19.6	15.8	22.8
TGC C 11.4 55.2 12.2 58.6 12.6 54.3 GAT D 23.9 50.2 21.8 43.4 21.8 46.5 GAA D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG E 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4 TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC 24.4 35.2 26.9 37.2 22.2 33.6 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9	GCG		6.3	8.7	8.1	10.9	7.4	10.7
GAT D 23.9 S0.2 21.8 43.4 21.8 46.5 GAC D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG E 38.8 55.4 44.2 66.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4 TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC G 24.4 35.2 26.9 37.2 22.2 33.6 GGA 17.0 24.6 16.0 22.1 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 13.2 CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 13.2 CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 27.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 27.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 27.7 20.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CAG Q 32.4 73.6 35.2 78.5 34.2 73.5 CCG 5.9 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA CCA 16.9 28.5 11.0 7.0 11.6 6.9 11.3 CCA 11.1 11.1 6.2 11.9 CCA 11.1 11.1 6.	TGT	C	9.3	44.8	8.6	41.4	10.6	45.7
GAC D 23.8 49.8 28.4 56.6 25.1 53.5 GAA E 31.2 44.6 26.6 37.6 29.0 42.3 GAG E 38.8 55.4 44.2 62.4 39.6 57.7 TTT F 15.2 45.7 14.3 40.5 17.6 46.4 TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC 24.4 35.2 26.9 37.2 22.2 33.6 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATC I 18.2 38.2 14.9 34.2 16.0 36.1	TGC	C	11.4	55.2	12.2	58.6	12.6	54.3
GAC GAA GAA GAA GAA GAA GAA GAA GAA GAA	GAT	D	23.9	50.2	21.8	43.4	21.8	46.5
GAG E 38.8 55.4 44.2 62.4 39.6 57.7 TTC F 15.2 45.7 14.3 40.5 17.6 46.4 TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC 24.4 35.2 26.9 37.2 22.2 33.6 GGA 17.0 24.6 16.0 22.1 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATT 18.2	GAC	D	23.8	49.8	28.4	56.6	25.1	53.5
TTT T	GAA	Г	31.2	44.6	26.6	37.6	29.0	42.3
TTC F 18.1 54.3 21.1 59.5 20.3 53.6 GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC GGA G 17.0 24.6 16.0 22.1 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.5 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT C 18.1 30.6 17.1 28.5 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT C 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA CCA P 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CCAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG CCG R 11.4 19.3 12.8 22.2 10.4 18.3 CCAA R 7.2 12.2 6.4 11.1 6.2 10.9	GAG	E	38.8	55.4	44.2	62.4	39.6	57.7
GGT	TTT	Г	15.2	45.7	14.3	40.5	17.6	46.4
GGT 13.3 19.2 12.9 17.8 10.8 16.4 GGC 24.4 35.2 26.9 37.2 22.2 33.6 GGA 17.0 24.6 16.0 22.1 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 11.9 <t< td=""><td>TTC</td><td>r</td><td>18.1</td><td>54.3</td><td>21.1</td><td>59.5</td><td>20.3</td><td>53.6</td></t<>	TTC	r	18.1	54.3	21.1	59.5	20.3	53.6
GGC GGA G 24.4 17.0 35.2 24.6 26.9 16.0 37.2 22.1 22.2 16.5 33.6 25.0 GGG 14.5 14.5 20.9 20.9 16.5 22.8 22.8 16.5 25.0 25.0 CAT CAC H 9.4 24.0 40.0 8.8 37.0 37.0 10.9 21.5 41.9 25.1 ATT ATT 18.2 23.8 38.2 24.9 14.9 34.2 36.0 36.1 36.1 36.1 ATC ATA 1 6.7 6.7 14.0 3.0 5.0 31.4 11.4 7.5 36.5 20.8 47.0 47.0 36.1 AAA AAA AAA AAA AAA AAA AAA AAA AAA AA	GGT		13.3	19.2	12.9	17.8	10.8	
GGA G 17.0 24.6 16.0 22.1 16.5 25.0 GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTA 6.7 <td></td> <td>0</td> <td>24.4</td> <td>35.2</td> <td>26.9</td> <td>37.2</td> <td></td> <td></td>		0	24.4	35.2	26.9	37.2		
GGG 14.5 20.9 16.5 22.8 16.5 25.0 CAT H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 <td></td> <td>G</td> <td></td> <td></td> <td></td> <td></td> <td>16.5</td> <td></td>		G					16.5	
CAT CAC H 9.4 40.0 8.8 37.0 10.9 41.9 CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC 1 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTG 17.6 19.0 18.8 20.1 19.6 19.6 CTA <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>								
CAC H 14.1 60.0 15.0 63.0 15.1 58.1 ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT 1 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 <td></td> <td></td> <td>9.4</td> <td></td> <td></td> <td></td> <td></td> <td></td>			9.4					
ATT 18.2 38.2 14.9 34.2 16.0 36.1 ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3		Н						
ATC I 22.8 47.8 23.7 54.3 20.8 47.0 ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 <td></td> <td></td> <td>18.2</td> <td></td> <td>14.9</td> <td></td> <td>16.0</td> <td></td>			18.2		14.9		16.0	
ATA 6.7 14.0 5.0 11.4 7.5 16.9 AAAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC P		I						
AAA K 29.9 42.2 23.6 36.5 24.4 43.3 AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30				14.0				
AAG K 40.9 57.8 41.1 63.5 31.9 56.7 TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7<	AAA	K	29.9	42.2	23.6	36.5	24.4	43.3
TTA 6.7 7.2 4.8 5.2 7.7 7.7 TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28			40.9	57.8			31.9	56.7
TTG 11.9 12.8 10.9 11.6 12.9 12.9 CTT L 13.3 14.4 10.9 11.7 13.2 13.2 CTC 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0			6.7				7.7	
CTT CTC L 13.3 14.4 10.9 11.7 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.6 19.5 19.5				12.8				12.9
CTC L 17.6 19.0 18.8 20.1 19.6 19.6 CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA P 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.		L		14.4	10.9	11.7	13.2	
CTA 6.7 7.2 5.6 6.0 7.2 7.2 CTG 36.5 39.4 42.4 45.4 39.6 39.5 ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 1			17.6	19.0	18.8	20.1	19.6	19.6
ATG M 24.6 100.0 23.3 100.0 22.0 100.0 AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2			6.7	7.2	5.6	6.0	7.2	7.2
AAT N 16.6 47.8 14.7 41.9 17.0 47.1 AAC 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9	CTG		36.5	39.4	42.4	45.4	39.6	39.5
AAC N 18.1 52.2 20.4 58.1 19.1 52.9 CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9	ATG	M	24.6	100.0	23.3	100.0	22.0	100.0
CCT	AAT	3.7	16.6	47.8	14.7	41.9	17.0	47.1
CCT 18.1 30.6 17.1 28.2 17.5 28.6 CCC 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9	AAC	N	18.1	52.2	20.4	58.1	19.1	52.9
CCC P 17.7 29.9 20.9 34.6 19.8 32.4 CCA 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9								
CCA P 16.9 28.5 15.4 25.6 16.9 27.7 CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9		P						
CCG 6.5 11.0 7.0 11.6 6.9 11.3 CAA CAG Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC CGA R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9								
CAA Q 11.6 26.4 9.6 21.5 12.3 26.5 CAG 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9								
CAG Q 32.4 73.6 35.2 78.5 34.2 73.5 CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9		Q						
CGT 5.9 10.1 5.7 9.9 4.5 7.9 CGC 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9								
CGC R 11.4 19.3 12.8 22.2 10.4 18.3 CGA 7.2 12.2 6.4 11.1 6.2 10.9		R						
CGA 7.2 12.2 6.4 11.1 6.2 10.9								
				17.6	12.3	21.3	11.4	20.1

AGA		13.0	22.1	9.9	17.1	12.2	21.5
AGG		11.0	18.7	10.6	18.4	12.0	21.2
TCT		14.3	19.8	13.3	18.3	15.2	18.7
TCC		15.9	22.1	17.4	24.0	17.7	21.8
TCA	S	10.5	14.5	9.2	12.7	12.2	15.0
TCG	S	3.5	4.8	4.4	6.1	4.4	5.4
AGT		11.0	15.3	9.6	13.2	12.1	14.9
AGC		16.9	23.5	18.7	25.7	19.5	24.0
ACT		14.3	27.7	12.1	23.4	13.1	24.6
ACC	т	18.1	35.0	20.9	40.3	18.9	35.5
ACA	T	14.0	27.1	12.7	24.4	15.1	28.4
ACG		5.3	10.3	6.2	12.0	6.1	11.5
GTT	V	13.1	20.2	10.4	16.5	11.0	18.1
GTC		15.1	23.4	15.8	25.0	14.5	23.9
GTA		7.9	12.3	6.2	9.8	7.1	11.7
GTG		28.5	44.0	30.8	48.7	28.1	46.3
TGG	W	10.6	100.0	11.1	100.0	13.2	100.0
TAT	Y	11.8	43.6	11.0	40.0	12.2	44.4
TAC	1	15.3	56.4	16.6	60.0	15.3	55.6

^{*} Fraction of each codon among all those for a given amino acid.

468

^{**} Downloaded from Codon Usage Database (16).

- Data S1. Sequences from GISAID's EpiCoVTM on which this study is based. The last
- column "317 genomes" indicates whether a genome was used in constructing the
- maximum likelihood phylogenetic tree and examining the synonymous triplet sites.